Incyte Corporation (NASDAQ:INCY) is one of the best immunotherapy stocks to buy according to hedge funds. Jefferies reiterated a Buy rating on Incyte Corporation (NASDAQ:INCY) on February 11, setting ...

Check out some of the companies making the biggest moves midday: Amentum Holdings — The defense contractor tumbled about 12% after fiscal first-quarter revenue and adjusted EBITDA missed Wall Street ...

Incyte (INCY) on Monday posted a Phase 3 trial win for tafasitamab, an antibody therapy it has developed with Xencor (XNCR), setting up a potential label expansion for the drug as a first-line option ...

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Incyte Corporation is one of them. Incyte Corporation (NASDAQ:INCY), a global biopharmaceutical ...

Fintel reports that on August 6, 2025, Wells Fargo upgraded their outlook for Incyte (NasdaqGS:INCY) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 6.78% Upside As of August 6, 2025, ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (NasdaqGS:INCY) from Outperform to Market Perform. Analyst Price Forecast Suggests 28.39% Upside As of March 4, ...

Check out the companies making headlines before the bell: Norwegian Cruise Line — Shares of the cruise operator rose 4% on the back of an upgrade from JPMorgan to overweight from neutral. The firm is ...

Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode. [Operator ...

Below is Validea's guru fundamental report for INCYTE CORP (INCY). Of the 22 guru strategies we follow, INCY rates highest using our Multi-Factor Investor model based on the published strategy of Pim ...